Because the antibody produced using the "anti-idiotypic" process closely resembles the original epitope of the antigen, these antibodies can be used to induce immune responses from cellular to antibody-antigen for a given antigen, e. g., TAA, when administered as a vaccine to a human.
Because the generated antibody shares a striking similarity with the original epitope of the antigen, these antibodies can be used to stimulate an immune response that progresses from cellular to antibody-antigen interactions for a particular antigen, like TAA, when administered as a vaccine to a human.